PSG9 and breast cancer: Similarly, the elevated expression of PSG9 in plasma specimens and tumorous tissue was strongly associated with poor clinical and prognostic parameters, such as metastatic lymph node tissues, distant metastasis, and shorter DFS in breast cancer patients (Liu et al., 2020).